Sebastian J Reinstadler1,2,3, Thomas Stiermaier1,2, Charlotte Eitel1,2, Bernhard Metzler3, Suzanne de Waha1,2, Georg Fuernau1,2, Steffen Desch1,2, Holger Thiele1,2, Ingo Eitel1,2. 1. Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lübeck, Medical Clinic II, University of Lübeck, Lübeck, Germany. 2. German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Lübeck, Germany. 3. University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.
Abstract
AIMS: Studies comparing reperfusion efficacy and myocardial damage between diabetic and non-diabetic patients with ST-elevation myocardial infarction (STEMI) are scarce and have reported conflicting results. The aim was to investigate the impact of preadmission diabetic status on myocardial salvage and damage as determined by cardiac magnetic resonance (CMR), and to evaluate its prognostic relevance. MATERIALS AND METHODS: We enrolled 792 patients with STEMI at 8 sites. CMR core laboratory analysis was performed to determine infarct characteristics. Major adverse cardiac events (MACE), defined as a composite of all-cause death, non-fatal re-infarction and new congestive heart failure, were recorded at 12 months. Patients were categorized according to preexisting diabetes mellitus (DM), and according to insulin-treated DM (ITDM) and non-insulin-treated DM (NITDM). RESULTS:One-hundred and sixty (20%) patients had DM and 74 (9%) were insulin-treated. There was no difference in the myocardial salvage index, infarct size, microvascular obstruction and left ventricular ejection fraction between all patient groups (all P > .05). Patients with DM were at higher risk of MACE (11% vs 6%, P = .03) than non-DM patients. After stratification according to preadmission anti-diabetic therapy, MACE rate was comparable between NITDM and non-DM (P > .05), whereas the group of ITDM patients had significantly worse outcome (P < .001). CONCLUSIONS:Diabetic patients with STEMI, especially those having ITDM, had an increased risk of MACE. The adverse clinical outcome was, however, not explained by an impact of DM on reperfusion success or myocardial damage. Clinical trial registry number: NCT00712101.
RCT Entities:
AIMS: Studies comparing reperfusion efficacy and myocardial damage between diabetic and non-diabeticpatients with ST-elevation myocardial infarction (STEMI) are scarce and have reported conflicting results. The aim was to investigate the impact of preadmission diabetic status on myocardial salvage and damage as determined by cardiac magnetic resonance (CMR), and to evaluate its prognostic relevance. MATERIALS AND METHODS: We enrolled 792 patients with STEMI at 8 sites. CMR core laboratory analysis was performed to determine infarct characteristics. Major adverse cardiac events (MACE), defined as a composite of all-cause death, non-fatal re-infarction and new congestive heart failure, were recorded at 12 months. Patients were categorized according to preexisting diabetes mellitus (DM), and according to insulin-treated DM (ITDM) and non-insulin-treated DM (NITDM). RESULTS: One-hundred and sixty (20%) patients had DM and 74 (9%) were insulin-treated. There was no difference in the myocardial salvage index, infarct size, microvascular obstruction and left ventricular ejection fraction between all patient groups (all P > .05). Patients with DM were at higher risk of MACE (11% vs 6%, P = .03) than non-DMpatients. After stratification according to preadmission anti-diabetic therapy, MACE rate was comparable between NITDM and non-DM (P > .05), whereas the group of ITDM patients had significantly worse outcome (P < .001). CONCLUSIONS:Diabeticpatients with STEMI, especially those having ITDM, had an increased risk of MACE. The adverse clinical outcome was, however, not explained by an impact of DM on reperfusion success or myocardial damage. Clinical trial registry number: NCT00712101.
Authors: Martin Reindl; Sebastian Johannes Reinstadler; Christina Tiller; Hans-Josef Feistritzer; Markus Kofler; Alexandra Brix; Agnes Mayr; Gert Klug; Bernhard Metzler Journal: Eur Radiol Date: 2018-12-13 Impact factor: 5.315
Authors: Maya Dia; Alexandre Paccalet; Bruno Pillot; Christelle Leon; Michel Ovize; Claire Crola Da Silva; Thomas Bochaton; Melanie Paillard Journal: Front Cardiovasc Med Date: 2021-03-26
Authors: Lara S F Konijnenberg; Peter Damman; Dirk J Duncker; Robert A Kloner; Robin Nijveldt; Robert-Jan M van Geuns; Colin Berry; Niels P Riksen; Javier Escaned; Niels van Royen Journal: Cardiovasc Res Date: 2020-03-01 Impact factor: 10.787
Authors: Ivan Lechner; Martin Reindl; Christina Tiller; Magdalena Holzknecht; Sarah Niederreiter; Agnes Mayr; Gert Klug; Christoph Brenner; Axel Bauer; Bernhard Metzler; Sebastian Johannes Reinstadler Journal: Int J Cardiovasc Imaging Date: 2021-09-02 Impact factor: 2.357